Lazard Capital Starts Endologix (ELGX) at Buy
More News related to ELGX
- Endologix to Present at Three Upcoming Conferences
- Endologix (ELGX) Tops Q3 EPS by 1c; Guides In-line
- Endologix Reports 47% Third Quarter 2009 Revenue Growth
- Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report
- Endologix to Report Third Quarter 2009 Financial Results on October 27, 2009
More News related to New Coverage
- Verizon (VZ) Executive McAdam Buys 17K Shares
- Herbalife (HLF) CEO Enters Trading Plan Covering 732K Shares
Lazard Capital initiates coverage on Endologix (Nasdaq: ELGX) with a Buy rating and $6 price target.
Endologix, Inc. engages in the development, manufacture, marketing, and sale of minimally invasive therapies for the treatment of vascular diseases.
Related Categories
New CoverageStocks Mentioned
-0.08Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
